Edition:
United States

Neogenomics Inc (NEO.OQ)

NEO.OQ on NASDAQ Stock Exchange Capital Market

7.59USD
4:00pm EDT
Change (% chg)

$-0.04 (-0.52%)
Prev Close
$7.63
Open
$7.64
Day's High
$7.64
Day's Low
$7.51
Volume
84,298
Avg. Vol
80,273
52-wk High
$9.87
52-wk Low
$6.15

Latest Key Developments (Source: Significant Developments)

NeoGenomics Q2 adjusted earnings per share $0.04
Tuesday, 26 Jul 2016 07:00am EDT 

Neogenomics Inc : Neogenomics reports 159% revenue growth to $63.1 million and strong gains in profitability in the second quarter of 2016 . Q2 adjusted earnings per share $0.04 . Q2 loss per share $0.07 . Q2 revenue $63.1 million versus i/b/e/s view $61.1 million . Q2 earnings per share view $0.03 -- Thomson Reuters I/B/E/S .Neogenomics inc says reiterated guidance for fiscal year 2016.  Full Article

Neogenomics files for stock shelf of up to $200 mln
Friday, 17 Jun 2016 04:05pm EDT 

Neogenomics Inc :Files for stock shelf of up to $200 million - SEC filing.  Full Article

Neogenomics Inc gives FY 2016 guidance
Tuesday, 1 Mar 2016 07:00am EST 

Neogenomics Inc:Expects FY 2016 revenue to be in the range of $240 - $250 million.Expects FY 2016 adjusted EBITDA to be in the range of $33 - $38 million.Expects FY 2016 adjusted net income to be in the range of $7 - $12 million, and adjusted diluted EPS to be in the range of $0.07 - $0.12 per share.  Full Article

NeoGenomics Inc completes acquisition of Clarient Inc
Wednesday, 30 Dec 2015 04:10pm EST 

NeoGenomics Inc:Announced that it has completed the acquisition of Clarient, Inc. and its wholly-owned subsidiary Clarient Diagnostic Services, Inc.  Full Article

NeoGenomics Inc sees fY 2015 revenue guidance near low end of prior range
Thursday, 29 Oct 2015 07:00am EDT 

NeoGenomics Inc:Expects full year 2015 revenue to be near the lower end of previous full-year revenue guidance of $100 - $103 million.  Full Article

NeoGenomics Inc signs definitive agreement to acquire Clarient Inc
Wednesday, 21 Oct 2015 07:00am EDT 

NeoGenomics Inc:Signs definitive agreement to acquire Clarient Inc.Transaction purchase price includes $80 million in cash.Deal consideration also includes $110 million in preferred stock, and 15 million shares of Neogenomics common stock.Preferred stock will be issued at $7.50 per share and is redeemable at the option of Neogenomics at any time over its ten year term.Deal to allow Neogenomics to broaden its offering of innovative cancer diagnostic tests to hospitals and physicians across the country.Expect revenue to more than double to $240- $250 mln,adjusted EBITDA to more than triple to between $33-$38 million on pro forma basis in 2016.Says as part of transaction, co's board will be expanded with the appointment of a new director from GE healthcare.After 3 years,ge healthcare to have option to convert preferred stock,accrued dividends to co's stock at $7.50 per share under some conditions.Says GE healthcare retains significant stake in Neogenomics and parties agree to collaborate on bioinformatics initiative.  Full Article

NeoGenomics Enters into National Agreement with Premier Inc
Wednesday, 2 Sep 2015 07:00am EDT 

NeoGenomics Inc:Announces that it has entered into a national group purchasing agreement with Premier Inc.Says the 3 year agreement secures for NeoGenomics the distinction of becoming first specialized oncology reference laboratory to become a preferred in-network lab option for all Premier member hospitals, cancer centers, pathology groups, & oncology/physician providers nationwide.  Full Article

Neogenomics Inc lowers FY 2015 revenue guidance
Thursday, 23 Jul 2015 07:00am EDT 

Neogenomics Inc:Says that it is lowering its previously issued revenue guidance for FY 2015 to $100 - 103 million, versus the previous guidance of $103 - 108 million.Says that it reiterated its expectation of a return to profitability in the H2 2015.  Full Article

Neogenomics Inc reaffirms FY 2015 revenue guidance
Tuesday, 28 Apr 2015 07:00am EDT 

Neogenomics Inc:Says that it reiterated its previously issued revenue guidance for FY 2015 of $103 - $108 million.  Full Article

More From Around the Web

BRIEF-NeoGenomics and Definiens to develop novel assays for clinical trials & clinical testing

* NeoGenomics and Definiens enter into agreement to develop novel assays for clinical trials & clinical testing